Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hypertension 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Sarcoma 1Radiation Injuries 1Prostatic Neoplasms 1Non-alcoholic Fatty Liver Disease 1Lymphoma, Follicular 1Lymphoma 1Hematologic Neoplasms 1Dyspnea 1Cardiotoxicity 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Radiotherapy 24Radiotherapy, Intensity-Modulated 8Radiosurgery 6Amifostine 5Low-Level Light Therapy 4Donepezil 4Cisplatin 4Carboplatin 4Surveys and Questionnaires 3Radiation 3Proton Therapy 3Paclitaxel 3Neuropsychological Tests 3Heavy Ion Radiotherapy 3Etoposide 3Chemotherapy, Adjuvant 3Chemoradiotherapy 3Brachytherapy 3Bevacizumab 3Surgical Procedures, Operative 2Radiation Dose Hypofractionation 2Patient Reported Outcome Measures 2Mental Status and Dementia Tests 2Esophagectomy 2Androgen Antagonists 2Adrenal Cortex Hormones 2sodium propionate 1sargramostim 1olaparib 1endostar protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Radiation Injuries × Lisinopril × Clear all
NCT05530655 2026-01-13

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

University of Rochester

Phase EARLY_PHASE1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡